series-a
Stage
1
Investors
About
Prothea Technologies develops medical technology that enables lung cancer biopsy and treatment to be performed in a single hospital visit by combining diagnostic sampling with therapy, aiming to reduce time-to-treat and improve patient outcomes. The company is validating its approach through clinical studies such as the Precision Lung trial (ISRCTN15093468).
Explore Prothea Technologies's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.